Compare USA & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USA | NRIX |
|---|---|---|
| Founded | 1986 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | N/A | 2020 |
| Metric | USA | NRIX |
|---|---|---|
| Price | $6.37 | $17.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $27.46 |
| AVG Volume (30 Days) | 880.5K | ★ 1.8M |
| Earning Date | 01-01-0001 | 01-27-2026 |
| Dividend Yield | ★ 9.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $83,687,000.00 |
| Revenue This Year | N/A | $59.40 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 48.32 |
| 52 Week Low | $5.62 | $8.18 |
| 52 Week High | $7.09 | $22.50 |
| Indicator | USA | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 62.14 | 45.83 |
| Support Level | $6.22 | $18.78 |
| Resistance Level | $6.34 | $19.54 |
| Average True Range (ATR) | 0.07 | 0.86 |
| MACD | 0.01 | -0.41 |
| Stochastic Oscillator | 98.08 | 10.77 |
Liberty All Star Equity Fund is a multi-managed fund. Its objective is to provide a high level of current income and long-term capital appreciation through investing principally in a diversified portfolio of equity securities. The fund invests in various sectors, including financials, information technology, healthcare, consumer discretionary, consumer staples, industrials, energy, materials, real estate, utilities, telecommunication, and other services.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.